http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2737025-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbdae384a9f1ad0588422c89ddc71a00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7dfb0281008cb570feea037cd350c8f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 |
| filingDate | 2013-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c61560e6beb873dbebd3895135c56221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b20612ef4c707967c0e8c2cfef000823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13a71f8dd638cc1dc35c0ffeb01352ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b089597d35dc707b96323312e9cefb57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f191c7e381f66b33a689e37b3d807f3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2f9a21860008301d34467dd563602f8 |
| publicationDate | 2020-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2737025-T3 |
| titleOfInvention | Methods and systems for screening compositions comprising sulfonated non-anticoagulant polysaccharides |
| abstract | A method of evaluating or selecting a plurality of compositions comprising a NASP (non-anticoagulant sulfate polysaccharide) to identify a composition that is suitable for treating a subject having a blood clotting disorder, the method comprising: determining the characteristics of : the coagulation activity and chemical composition of each composition; the molecular structure of each NASP; wherein said determination of coagulation activity comprises evaluating the EC50 for the procoagulant activity of the composition by means of calibrated automated thrombography (CAT), the procoagulant window of the composition, and calculating the ratio of the procoagulant activity to the anticoagulant activity of the composition. ; wherein said determining the molecular structure comprises determining the molecular weight of the NASP, the percentage by weight of sulfur of the NASP and the content of fucosa and alginate of the NASP; and wherein said determination of the chemical composition comprises determining the elemental components of the composition, and wherein said determination of the elemental components of the composition comprises determining the impurity content of the composition; wherein said method further comprises comparing the determined characteristics of the plurality of compositions comprising a NASP; wherein said method further comprises determining that one or more of the plurality of compositions may be suitable for treating a subject having a blood clotting disorder when the composition comprises: an EC50 value for procoagulant activity of 0.3 µg / ml or less as determined by CAT; a procoagulant window of 0.1 to 100 µg / ml; a ratio of the procoagulant activity to the anticoagulant activity of the composition that is 10 or greater; a NASP molecular weight that is 160 kDa or less; a fucose content of the NASP that is 60% fucose or greater; NASP alginate content that is 10% alginate or less; a weight percentage of sulfur in the NASP that is 8% sulfur by weight or greater; and a weight percentage of impurities in the composition that is 0.1% impurities by weight or less. |
| priorityDate | 2012-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 259.